Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Department of Hematology Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
Biomed Res Int. 2021 Mar 11;2021:6643948. doi: 10.1155/2021/6643948. eCollection 2021.
AML is a heterogeneous disease both in genomic and proteomic backgrounds, and variable outcomes may appear in the same cytogenetic risk group. Therefore, it is still necessary to identify new antigens that contribute to diagnostic information and to refine the current risk stratification.
The expression of C-type lectin-like molecule-1 (CLL-1) in AML blasts was examined in 52 patients with newly diagnosed or relapsed/refractory AML and was compared with two other classic markers CD33 and CD34 in AML, in order to assess the value of CLL-1 as an independent biomarker or in combination with other markers for diagnosis in AML. Subsequently, the value of CLL-1 as a biomarker for prognosis was assessed in this malignant tumor.
The results showed that CLL-1 was expressed on the cell surface of the majority of AML blasts (78.8%) and also expressed on leukemic stem cells in varying degree but absent on normal hematopoietic stem cells. Notably, CLL-1 was able to complement the classic markers CD33 or CD34. After dividing the cases into CLL-1 and CLL-1 groups according to cutoff 59.0%, we discovered that event-free survival and overall survival (OS) of the CLL-1 group were significantly lower than that of the CLL-1 group, and low CLL-1 expression seems to be independently associated with shorter OS.
These preliminary observations identified CLL-1 as a biomarker for diagnosis and prognosis of AML.
急性髓细胞白血病（AML）在基因组和蛋白质组背景下均具有异质性，相同细胞遗传学风险组中可能出现不同的预后。因此，仍有必要鉴定新的抗原，以提供诊断信息并完善当前的风险分层。
检测了 52 例初诊或复发/难治性 AML 患者中 C 型凝集素样分子-1（CLL-1）在 AML blasts 中的表达，并与 AML 中的另外两个经典标志物 CD33 和 CD34 进行比较，以评估 CLL-1 作为独立生物标志物或与其他标志物联合用于 AML 诊断的价值。随后，评估了 CLL-1 作为该恶性肿瘤预后标志物的价值。
结果表明，CLL-1 表达于大多数 AML blasts 的细胞表面（78.8%），并在不同程度上表达于白血病干细胞，但不存在于正常造血干细胞中。值得注意的是，CLL-1 能够补充经典标志物 CD33 或 CD34。根据截值 59.0%将病例分为 CLL-1 和 CLL-1 组后，我们发现 CLL-1 组的无事件生存（EFS）和总生存（OS）显著低于 CLL-1 组，低 CLL-1 表达似乎与 OS 缩短独立相关。
这些初步观察结果表明 CLL-1 可作为 AML 诊断和预后的生物标志物。
